{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:03:24Z","timestamp":1767139404520,"version":"build-2238731810"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The optimal salvage therapy in relapsed\/refractory Hodgkin lymphoma (R\/R HL) has not been defined so far. The goal of this multicenter retrospective study was to evaluate efficacy and safety of BGD (bendamustine, gemcitabine, dexamethasone) as a second or subsequent line of therapy in classical R\/R HL. We have evaluated 92 consecutive R\/R HL patients treated with BGD. Median age was 34.5 (19\u201382) years. Fifty-eight patients (63%) had received 2 or more lines of chemotherapy, 32 patients (34.8%) radiotherapy, and 21 patients (22.8%) an autologous hematopoietic stem cell transplantation (autoHCT). Forty-four patients (47.8%) were resistant to first line of chemotherapy. BGD therapy consisted of bendamustine 90 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    on days 1 and 2, gemcitabine 800 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    on days 1 and 4, dexamethasone 40 mg on days 1\u20134. Median number of BGD cycles was 4 (2\u20137). The following adverse events \u2265 3 grade were noted: neutropenia (22.8%), thrombocytopenia (20.7%), anemia (15.2%), infections (10.9%), AST\/ALT increase (2.2%), and skin rush (1.1%). After BGD therapy, 51 (55.4%) patients achieved complete remission, 23 (25%)\u2014partial response, 7 (7.6%)\u2014stable disease, and 11 (12%) patients experienced progression disease. AutoHCT was conducted in 42 (45.7%) patients after BGD therapy, and allogeneic HCT (alloHCT) in 16 (17.4%) patients. Median progression-free survival was 21 months. BGD is a highly effective, well-tolerated salvage regimen for patients with R\/R HL, providing an excellent bridge to auto- or alloHCT.\n                  <\/jats:p>","DOI":"10.1007\/s00277-021-04448-5","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T09:10:30Z","timestamp":1614157830000},"page":"1755-1767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed\/refractory Hodgkin Lymphoma"],"prefix":"10.1007","volume":"100","author":[{"given":"Ryszard","family":"Swoboda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanda","family":"Knopi\u0144ska-Pos\u0142uszny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Chmielowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Drozd-Soko\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Paszkiewicz-Kozik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"Kulikowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Taszner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W\u0142odzimierz","family":"Mendrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Najda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Czerw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Olszewska-Szopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Czy\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Giza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Spycha\u0142owicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edyta","family":"Subocz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Szwedyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Krzywon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Wilk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0986-8936","authenticated-orcid":false,"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"4448_CR1","doi-asserted-by":"publisher","unstructured":"Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, Bello CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N (2018) NCCN Guidelines Insights: Hodgkin lymphoma, Version 1.2018. J Natl Compr Canc Netw 16:245-254. https:\/\/doi.org\/10.6004\/jnccn.2018.0013","DOI":"10.6004\/jnccn.2018.0013"},{"key":"4448_CR2","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, M\u00fcller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V, German Hodgkin\u2019s Lymphoma Study Group, Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet 359:2065\u20132071. https:\/\/doi.org\/10.1016\/S0140-6736(02)08938-9","journal-title":"Lancet"},{"key":"4448_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-l","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet 341:1051\u20131054. https:\/\/doi.org\/10.1016\/0140-6736(93)92411-l","journal-title":"Lancet"},{"key":"4448_CR4","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","volume":"119","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, Horwitz S, Moskowitz AJ, Noy A, Palomba L, Perales MA, Portlock C, Straus D, Maragulia JC, Schoder H, Yahalom J (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119:1665\u20131670. https:\/\/doi.org\/10.1182\/blood-2011-10-388058","journal-title":"Blood"},{"key":"4448_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood.v97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O\u2019Brien JP, Straus D, Portlock CS, Yahalom J (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97:616\u2013623. https:\/\/doi.org\/10.1182\/blood.v97.3.616","journal-title":"Blood"},{"key":"4448_CR6","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","volume":"13","author":"A Josting","year":"2002","unstructured":"Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, D\u00f6rken B, Hossfeld DK, Diehl V, Engert A, Participating Centers (2002) Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease. Ann Oncol 13:1628\u20131635. https:\/\/doi.org\/10.1093\/annonc\/mdf221","journal-title":"Ann Oncol"},{"key":"4448_CR7","first-page":"10","volume":"9","author":"M Ramzi","year":"2015","unstructured":"Ramzi M, Rezvani A, Dehghani M (2015) GDP versus ESHAP Regimen in Relapsed and\/or refractory Hodgkin lymphoma: a comparison study. Int J Hematol Oncol Stem Cell Res 9:10\u201314","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"4448_CR8","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","volume":"18","author":"NL Bartlett","year":"2007","unstructured":"Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP, Cancer Leukemia Group B (2007) Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804. Ann Oncol 18:1071\u20131079","journal-title":"Ann Oncol"},{"key":"4448_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica 92:35\u201341","journal-title":"Haematologica"},{"key":"4448_CR10","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3109\/10428194.2010.491137","volume":"51","author":"AK Gopal","year":"2010","unstructured":"Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT, Garrison MA, Gjerset GF, Lonergan M, Murphy AE, Smith JC, Pagel JM (2010) Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 51:1523\u20131529","journal-title":"Leuk Lymphoma"},{"key":"4448_CR11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","volume":"31","author":"AJ Moskowitz","year":"2013","unstructured":"Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ, Graustein T, Zelenetz AD, Moskowitz CH (2013) Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 31:456\u2013460. https:\/\/doi.org\/10.1200\/JCO.2012.45.3308","journal-title":"J Clin Oncol"},{"key":"4448_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O\u2019Connor OA, Josephson N, Wang Y, Advani R (2018) Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 132:40\u201348. https:\/\/doi.org\/10.1182\/blood-2017-11-815183","journal-title":"Blood"},{"key":"4448_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","volume":"19","author":"OA O\u2019Connor","year":"2018","unstructured":"O\u2019Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J (2018) Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol 19:257\u2013266. https:\/\/doi.org\/10.1016\/S1470-2045(17)30912-9","journal-title":"Lancet Oncol"},{"key":"4448_CR14","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","volume":"34","author":"A Santoro","year":"2016","unstructured":"Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Salvi F, Merli F, Anastasia A, Luminari S, Annechini G, Gotti M, Peli A, Liberati AM, Di Renzo N, Castagna L, Giordano L, Carlo-Stella C (2016) Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase ii study. J Clin Oncol 34:3293\u20133299. https:\/\/doi.org\/10.1200\/JCO.2016.66.4466","journal-title":"J Clin Oncol"},{"key":"4448_CR15","first-page":"4098","volume":"130","author":"E Paszkiewicz-Kozik","year":"2017","unstructured":"Paszkiewicz-Kozik E, Zaucha J, Tyczy\u0144ska A, Szymanski M, Targonski L, Drozd-Sokolowska J, Wojciechowska-Lampka E, Tajer J, Kurczab P, Romejko-Jarosinska J, Osowiecki M, Walewski J (2017) Bendamustine, gemcitabine and dexamethasone chemotherapy is effective salvage and stem-cell mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma\u2014early results of the polish lymphoma research group study. Blood 130:4098","journal-title":"Blood"},{"key":"4448_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.achaem.2015.07.094","volume":"46","author":"W Knopi\u0144ska-Pos\u0142uszny","year":"2015","unstructured":"Knopi\u0144ska-Pos\u0142uszny W, Kulikowski W, Paszkiewicz-Kozik E, Czy\u017c A, Giza A, Chmielowska E, Drozd-Soko\u0142owska J, Subocz E, Mendrek W, Spycha\u0142owicz W (2015) Zastosowanie bendamustyny z gemcytabin\u0105 i deksametazonem w leczeniu pierwotnie opornej i nawrotowej postaci ch\u0142oniaka Hodgkina\u2013wieloo\u015brodkowe badanie obserwacyjne Polskiej Grupy Badawczej Ch\u0142oniak\u00f3w (PLRG). Acta Haematol Pol 46:58\u201359","journal-title":"Acta Haematol Pol"},{"key":"4448_CR17","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer\/Dutch Hemato-Oncology Group, Grupo Espa\u00f1ol de M\u00e9dula \u00d3sea, German High-Grade Lymphoma Study Group, German Hodgkin\u2019s Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group; United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"4448_CR18","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf; Published: May 28, 2009"},{"key":"4448_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/cncr.21587","volume":"106","author":"J Kuruvilla","year":"2006","unstructured":"Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M (2006) Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106:353\u2013360","journal-title":"Cancer"},{"key":"4448_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00277-010-1113-z","volume":"90","author":"E Suyan\u0131","year":"2011","unstructured":"Suyan\u0131 E, Sucak GT, Ak\u0131 \u015eZ, Ye\u011fin ZA, \u00d6zkurt ZN, Ya\u011fc\u0131 M (2011) Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 90:685\u2013691. https:\/\/doi.org\/10.1007\/s00277-010-1113-z","journal-title":"Ann Hematol"},{"key":"4448_CR21","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/cncr.32640","volume":"126","author":"JB Cohen","year":"2020","unstructured":"Cohen JB, Wei L, Maddocks KJ, Christian B, Heffner LT, Langston AA, Lechowicz MJ, Porcu P, Flowers CR, Devine SM, Blum KA (2020) Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent\/refractory Hodgkin lymphoma: results of a phase 1\/2 study. Cancer 126:1235\u20131242","journal-title":"Cancer"},{"key":"4448_CR22","doi-asserted-by":"crossref","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30:2183-2189","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"4448_CR23","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","volume":"21","author":"R Chen","year":"2015","unstructured":"Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ (2015) Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 21:2136\u20132140","journal-title":"Biol Blood Marrow Transplant"},{"key":"4448_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311\u2013319","journal-title":"N Engl J Med"},{"key":"4448_CR25","doi-asserted-by":"crossref","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol 36:1428-1439","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"4448_CR26","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH (2016) Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34:3733\u20133739","journal-title":"J Clin Oncol"},{"key":"4448_CR27","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH, KEYNOTE-087 (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 35:2125\u20132132","journal-title":"J Clin Oncol"},{"key":"4448_CR28","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","volume":"129","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, Fran\u00e7ois S, Stamatoullas-Bastard A, Rohrlich PS, Labussi\u00e8re Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P (2017) Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma. Blood 129:1380\u20131388 1182\/blood-2016-09-738385","journal-title":"Blood"},{"key":"4448_CR29","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/bmt.2017.158","volume":"52","author":"Y Oshima","year":"2017","unstructured":"Oshima Y, Tanimoto T, Yuji K, Tojo A (2017) Association between GvHD and nivolumab in the FDA adverse event reporting system. Bone Marrow Transplant 52:1463\u20131464. https:\/\/doi.org\/10.1038\/bmt.2017.158","journal-title":"Bone Marrow Transplant"}],"updated-by":[{"DOI":"10.1007\/s00277-021-04503-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04448-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04448-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04448-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T21:55:14Z","timestamp":1627682114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04448-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["4448"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04448-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"30 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-021-04503-1","URL":"https:\/\/doi.org\/10.1007\/s00277-021-04503-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to Polish regulations, this was a retrospective study and it does not require approval of the bioethical committee. The study was approved by the board of The Polish Lymphoma Research Group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}